S-1: Abpro Holdings Files for Resale of Common Stock and Warrants Following Business Combination

Abpro Holdings, Inc. has filed a registration statement for the resale of up to 31.8 million shares of common stock and 13.9 million warrants by existing securityholders, along with the primary issuance of up to 28.9 million shares upon warrant exercise.

Summary

• Abpro Holdings, Inc. has filed a registration statement for the resale of securities by existing shareholders and warrant holders.
• The filing includes the resale of up to 31,785,312 shares of common stock and 13,850,000 warrants.
• The company is also registering the primary issuance of up to 28,850,000 shares of common stock upon the exercise of outstanding warrants.
• These securities were issued in connection with a business combination with Atlantic Coastal Acquisition Corp. II and a private placement.
• The company will not receive any proceeds from the resale of common stock or warrants by the selling securityholders, except for amounts received upon the exercise of the warrants.
• The number of shares being registered represents approximately 117% of the total common stock outstanding as of December 23, 2024.
• The sale of these securities could result in a significant decline in the public trading price of the company's common stock.

Sentiment

Score: 3

Explanation: The document presents a mix of positive and negative information, but the overall tone is cautious due to the company's financial situation and the risks associated with its business. The potential for a significant decline in the stock price and the uncertainty around future funding contribute to the low sentiment score.

Positives

• The company will receive proceeds from the exercise of warrants for cash.
• The registration of these securities satisfies certain registration rights granted by the company.

Negatives

• The sale of the securities being registered could result in a significant decline in the public trading price of the company's common stock.
• Some selling securityholders have an incentive to sell because they acquired their shares at lower prices than public investors.
• The company believes that if the market price for its common stock is less than the exercise price of $11.50, warrant holders will be unlikely to exercise their warrants.

Risks

• The company's management has concluded that uncertainties around its ability to raise additional capital raise substantial doubt about its ability to continue as a going concern.
• The company's product candidates are in early stages of development and have never been tested in a human subject.
• The company may not be able to obtain U.S. or foreign regulatory approval for its product candidates.
• The company faces competition from entities that have developed or may develop product candidates for the treatment of the diseases that it is initially targeting.
• The company may be unable to protect its intellectual property rights throughout the world.
• The company may be subject to litigation and legal proceedings that may substantially increase its costs and harm its business.
• The company's internal computer systems, or those of its contractors, may fail or suffer security breaches, which could result in a material disruption of its product development programs.
• The company's current operations are concentrated across two locations in close proximity, and it may be adversely affected by natural disasters.
• The company is an emerging growth company, and its reduced SEC reporting requirements may make its shares less attractive to investors.
• An active market for the company's securities may not develop, which would adversely affect the liquidity and price of its securities.
• The company's failure to meet Nasdaq's continued listing requirements could result in a delisting of its common stock and public warrants.
• The market price for the company's common stock may decline following the business combination.
• The company's stockholders may experience dilution in the future.
• There is no guarantee that the warrants will ever be in the money; they may expire worthless or the terms of warrants may be amended.

Future Outlook

The company believes that its existing cash and cash equivalents, together with the proceeds from the Business Combination and the PIPE Offering, will be insufficient to meet its anticipated cash needs for working capital, financial liabilities and capital expenditures for the next 12 months from the date of this filing. The company will need to raise additional capital to fund its operations and drug development.

Management Comments

• The company believes the likelihood that warrant holders will exercise their warrants is dependent upon the market price of its common stock.
• The company believes that if the market price for its common stock is less than the exercise price of $11.50, warrant holders will be unlikely to exercise their warrants.

Industry Context

The document highlights the competitive nature of the biotechnology and pharmaceutical industries, with numerous companies developing treatments for the same diseases that Abpro is targeting. The document also notes the intense and rapidly evolving competition in the antibody and immunoregulatory therapeutics fields.

Comparison to Industry Standards

• The document mentions several competitors, including AnaptysBio, Inc., Bristol-Myers Squibb Company, Genmab A/S, Ichnos Glenmark Innovation, Janux Therapeutics, Regeneron Pharmaceuticals, Inc., Roche AG, and Xencor Inc., which are developing antibodies for the treatment of cancer and autoimmune diseases.
• The document also notes that some of Abpro's product candidates will compete against traditional cancer therapies, such as chemotherapy, as well as immune-based treatments for cancer, such as CAR T and TCR therapies, developed or currently marketed by Bellicum Pharmaceuticals, Inc., Bluebird bio, Inc., Bristol-Myers Squibb Company, Cellectis S.A., Gilead Sciences, Inc., Novartis AG, Precigen, Inc., AstraZeneca and Genentech, Inc. (a member of the Roche Group, or Genentech/Roche).
• The document states that many of Abpro's competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than Abpro does.

Legal Proceedings

• The company has been, is, and may in the future become, party to lawsuits and legal proceedings including, without limitation, actions and proceedings in the ordinary course of business relating to its collaboration partners, directors, officers, stockholders, intellectual property rights, employment matters and the safety or efficacy of its products.
• The company is in discussions with MSK about a possible settlement related to a terminated license agreement.

Related Party Transactions

• The document details several related party transactions, including a promissory note agreement with an executive, a consulting agreement with a director, and a collaboration agreement with Abpro Bio International, Inc.

Stakeholder Impact

• The sale of the securities being registered could result in a significant decline in the public trading price of the company's common stock, impacting shareholders.
• The company's ability to raise additional capital and continue as a going concern is uncertain, which could affect employees and other stakeholders.
• The company's product candidates are in early stages of development and have never been tested in a human subject, which could impact patients.

Next Steps

• The company plans to initiate a Phase 1/2 clinical trial of ABP-102 in the first half of 2026, focusing on HER2+ breast and gastric cancers.
• The company plans to advance ABP-201 into Phase 1 clinical trials also in the second half of 2026 for the treatment of Wet AMD.

Key Dates

Keywords

common stock, warrants, resale, registration statement, business combination, biotechnology, pharmaceutical, capital raise, equity offering, securities